CORRECTION: Marker Therapeutics (MRKR) - MRKR’s Dilution Trap is Actually Bigger Than I Thought

In my March 13 update for Marker Therapeutics (MRKR), I warned that the company was facing a Nasdaq delisting and setting up a dilution trap via a reverse stock split. I was wrong about the mechanism. A sharp-eyed subscriber caught the error: MRKR is trading above the $1.00 Nasdaq minimum bid requirement, and there is no reverse stock split on the docket for their upcoming May shareholder meeting.

I was reviewing proxy statements for several cash-bleeding micro-caps that week, and I crossed my notes. Given the stock price at the time, I mapped the standard struggling biotech reverse split playbook onto Marker’s proxy.

Here is the irony: The actual mechanism buried in the proxy arguably makes the dilution threat significantly worse than I initially modeled.

The 100-Million-Share ATM Weapon

Management is not using a reverse split to hide dilution. Instead, Proposal 3 in the proxy asks shareholders to amend the corporate charter to increase the total number of authorized common shares from 30,000,000 to 130,000,000.

The Dilution Math

Marker currently has roughly 16.7 million shares outstanding. If Proposal 3 passes, management will instantly gain a reservoir of over 100 million blank check shares. The proxy explicitly notes that this increase is intended to provide flexibility to issue shares for capital-raising transactions without needing further stockholder approval.

The Cash Reality

The 10-K confirms their cash runway only extends into Q3 2026, assuming no new grant funds arrive. Their auditors have formally issued a going concern warning. They are legally and financially obligated to raise capital.

The Verdict (Unchanged): SELL INTO THE RIPS

The core investment thesis remains identical, but the scale of the dilution gap threat has arguably magnified.

The MAR-T cell science remains elegant, and the market is eagerly awaiting the 1H 2026 dose-expansion data from the APOLLO lymphoma trial. If that data is good, the stock should pop. But the moment it does, management now has the clearance to dump up to 100 million new shares into the open market via their At-The-Market (ATM) facility to fund their operations past Q3 2026.

Right now, this stock appears to be set up as a highly engineered dilution machine waiting for a clinical PR to serve as exit liquidity. Trade accordingly.

This report is for informational and educational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities. The scientific analysis contained herein is for investment due diligence purposes only and should not be interpreted as medical guidance or treatment recommendations. Biotech investing is highly volatile.